Securities



Smelling the coffee

Uchi's 2Q17 results were above expectations. We raise our 2017-19 EPS forecasts by 14%-30% to account for the improved near-term outlook resulting from better demand for high-end automated coffee machines from its end-customer Jura. With the improved prospects, undemanding valuation (2018E PE of 13x) and attractive 2018E yield of 7.6%, we upgrade Uchi to BUY and with a higher TP of RM2.67.

1H17 results above expectations

Revenue and profits for 1H17 were ahead of our expectations (core net profit was 56% of our previous 2017 forecast and 54% of the street's) largely due to better-than-expected sales. 1H17 revenue was up 11% due to stronger demand for Uchi's coffee modules and biotech laboratory equipment. On a sequential basis, while 2Q17 revenue was weaker due to both the lower sales volumes and adverse currency impact, the 9ppt improvement in the EBITDA margin lifted core earnings by 17% qoq. We think that the sharp margin improvement is not sustainable; the EBITDA margin has traditionally been volatile because of changes in the product mix as well as R&D expenditure that is expensed. We think a longer-term EBITDA margin at the 50% level would be sustainable given Uchi's niche product manufacturing strategy.

Positive outlook revision - it's been a while

After years of a rather somber outlook (due to weak macro conditions in Europe, its key market), management has guided for mid to high single-digit revenue growth (US\$ terms) for 2017 (1H17: +3%) on the back of incoming orders that have been positive and encouraging. We think that this could be due to its customer Jura, which is gaining market share in its own markets (+9.5% unit growth in 2016) and aiming for further growth this year.

Upgrade to BUY; 12-month TP raised to RM2.67

We like Uchi's management team, niche market strategy, strong cash position and 'sticky' customers. In view of the more upbeat guidance, we raise our 2017-19E EPS by 14-30%. With likely stronger earnings growth and more attractive dividend yields of 7-8% (2017-19E), we now value the stock using a PE of 16x (previously 14x) on CY18E EPS, which is at a 10% discount to the target PE for the FBMKLCI. With the EPS and PE multiple revisions, we raise our TP to RM2.67 (from RM1.81) and upgrade the stock to BUY from Hold. Risks: a slowdown in global demand for automated high-end coffee machines, new competition and a loss of its customer base.

Earnings & Valuation Summary

| J | | | | | |
|-----------------------|-------|-------|-------|-------|-------|
| FYE 31 Dec | 2015 | 2016 | 2017E | 2018E | 2019E |
| Revenue (RMm) | 112.6 | 120.9 | 131.5 | 147.8 | 154.6 |
| EBITDA (RMm) | 58.1 | 59.9 | 67.1 | 75.4 | 78.9 |
| Pretax profit (RMm) | 50.4 | 57.1 | 65.8 | 74.2 | 77.6 |
| Net profit (RMm) | 49.3 | 55.5 | 64.5 | 72.7 | 76.1 |
| EPS (sen) | 11.3 | 12.7 | 14.8 | 16.7 | 17.4 |
| PER (x) | 18.6 | 16.5 | 14.2 | 12.6 | 12.1 |
| Core net profit (RMm) | 54.9 | 58.2 | 64.5 | 72.7 | 76.1 |
| Core EPS (sen) | 12.6 | 13.3 | 14.8 | 16.7 | 17.4 |
| Core EPS growth (%) | 43.1 | 6.1 | 10.8 | 12.7 | 4.6 |
| Core PER (x) | 16.7 | 15.7 | 14.2 | 12.6 | 12.1 |
| Net DPS (sen) | 11.0 | 13.0 | 14.0 | 16.0 | 17.0 |
| Dividend Yield (%) | 5.2 | 6.2 | 6.7 | 7.6 | 8.1 |
| EV/EBITDA (x) | 12.8 | 12.0 | 10.6 | 9.3 | 8.7 |
| | | | | | |
| Chg in EPS (%) | | | +14.0 | +26.1 | +29.6 |
| Affin/Consensus (x) | | | 1.1 | 1.3 | 1.3 |

Source: Company, Affin Hwang forecasts, Bloomberg

Out think. Out perform.

Results Note

Uchi Tech

Sector: Technology

UCHI MK

RM2.10 @ 23 August 2017

BUY (upgrade)

Upside: 27%

Price Target: RM2.67

Previous Target: RM1.81



Price Performance

| | 1M | 3M | 12M |
|-------------|--------|--------|--------|
| Absolute | +11.7% | +13.5% | +27.3% |
| Rel to KLCI | +10.8% | +13.1% | +20.8% |

Stock Data

| Issued shares (m) | 438.0 |
|-------------------------------|-------------|
| Mkt cap (RMm)/(US\$m) | 919.8/215.0 |
| Avg daily vol - 6mth (m) | 0.7 |
| 52-wk range (RM) | 1.62-2.12 |
| Est free float | 46.7% |
| BV per share (RM) | 0.59 |
| P/BV (x) | 3.03 |
| Net cash/ (debt) (RMm) (2Q17) | 211.8 |
| ROE (2017E) | 25% |
| Derivatives | Nil |
| Shariah Compliant | Yes |
| | |

Key Shareholders

| .6 | Eastbow International Ltd | 19.0% |
|----|---------------------------|-------|
| .9 | Ironbridge Worldwide | 8.1% |
| .6 | LTH | 5.8% |
| .1 | | |

4 Source: Affin Hwang, Bloomberg

Kevin Low (603) 2146 7479 kevin.low@affinhwang.com

Securities



Out think. Out perform.

| Fig 1: Results Compa | rison | | | | | |
|----------------------|--------|---------|---------|--------|---------|---|
| FYE 31 Dec (RMm) | 2Q17 | QoQ | YoY | 1H17 | YoY | Comments |
| (*******) | | % chg | % chg | | % chg | |
| Revenue | 31.5 | (3.1) | 15.9 | 63.9 | 10.7 | 2Q17 revenue weaker due to lower US\$ sales, which declined 0.7% qoq, and adverse impact from appreciation of the RM. For 1H17, sales in US\$ terms were higher by 3% yoy |
| Op costs | (13.9) | (19.5) | 2.5 | (31.3) | 7.1 | |
| EBITDA | 17.5 | 15.6 | 29.4 | 32.7 | 14.3 | |
| EBITDA margin (%) | 55.7 | +9.0ppt | +5.8ppt | 51.1 | +1.6ppt | 1H17 margin largely stable. Sharp improvement in 2Q17 due to low base in 1Q17 |
| Depn and amort | (1.6) | (0.3) | 4.9 | (3.1) | 4.4 | |
| EBIT | 15.9 | 17.5 | 32.4 | 29.5 | 15.5 | |
| Int expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Int and other inc | 1.6 | 3.2 | 27.7 | 3.1 | 19.1 | |
| EI | (0.9) | 72.0 | (17.3) | (1.3) | (38.4) | Largely related to forex |
| Pretax profit | 16.7 | 14.1 | 36.1 | 31.3 | 20.4 | |
| Core pretax | 17.5 | 16.0 | 32.0 | 32.7 | 15.8 | |
| Tax | (0.4) | (3.7) | (1.6) | (0.7) | 6.4 | |
| Tax rate (%) | 2.2 | n.m | n.m | 2.4 | n.m | |
| MI | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net profit | 16.3 | 14.6 | 37.3 | 30.6 | 20.8 | |
| EPS (sen) | 3.7 | 14.6 | 37.3 | 7.0 | 20.8 | |
| Core net profit | 17.2 | 16.5 | 32.9 | 31.9 | 16.1 | Accounts for 56% and 54% of our previous and consensus 2017 estimates |

Source: Affin Hwang, Company

Securities



Out think. Out perform.

Equity Rating Structure and Definitions

| BUY | Total return is expected to exceed +10% over a 12-month period | | | |
|---|--|--|--|--|
| HOLD | Total return is expected to be between -5% and +10% over a 12-month period | | | |
| SELL | Total return is expected to be below -5% over a 12-month period | | | |
| NOT RATED | Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation | | | |
| The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months. | | | | |
| OVERWEIGHT | Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months | | | |
| NEUTRAL | Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months | | | |
| UNDERWEIGHT | Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months | | | |

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (express or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest arising as a result of publication and distribution of investment research reports. Under no circumstances shall the Company, is associates and/or any person related to it be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or change without prior notice. Under no circumstances shall this report are that of the Company, as of this date and subject to change without prior notice. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company and/or any of its directors mady are in the securities mentioned therein. The Company may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences and hence an independent evaluation is essential. Investors are advised to independently evaluate particular investments and strategies and to seek independent financial, legal and other advice on the information and/or opinion contained in this report before investing or participating in any of the securities or investment strategies or transactions discussed in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

The Company's research, or any portion thereof may not be reprinted, sold or redistributed without the consent of the Company.

The Company, is a participant of the Capital Market Development Fund-Bursa Research Scheme, and will receive compensation for the participation.

This report is printed and published by: Affin Hwang Investment Bank Berhad (14389-U) A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead, 69, Jalan Raja Chulan, 50200 Kuala Lumpur, Malaysia.

T : + 603 2146 3700 F : + 603 2146 7630 research@affinhwang.com

www.affinhwang.com